At the same time, ATF4 and STAT3 inhibitors may have further applications in sorafenib-resistant liver cancer patients, and understanding the role of ATF4/STAT3 molecular pathways in HCC progression will contribute to the development of potential drugs for targeted treatment of liver cancer. The gene discussed is STAT3; the disease is hepatocellular carcinoma.